Edition:
United States

Masimo Corp (MASI.O)

MASI.O on Nasdaq

89.66USD
20 Apr 2018
Change (% chg)

$0.44 (+0.49%)
Prev Close
$89.22
Open
$88.87
Day's High
$89.71
Day's Low
$88.61
Volume
376,574
Avg. Vol
501,734
52-wk High
$104.71
52-wk Low
$80.69

Chart for

About

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $4,629.71
Shares Outstanding(Mil.): 51.64
Dividend: --
Yield (%): --

Financials

  MASI.O Industry Sector
P/E (TTM): 28.60 35.59 33.60
EPS (TTM): 3.14 -- --
ROI: 25.77 14.13 13.19
ROE: 27.64 16.91 15.00

BRIEF-Masimo Announces CE Marking Of Rad-97 Pulse CO-Oximeter With Integrated NomoLine Capnography

* MASIMO ANNOUNCES CE MARKING OF RAD-97™ PULSE CO-OXIMETER® WITH INTEGRATED NOMOLINE™ CAPNOGRAPHY

Apr 10 2018

BRIEF-Masimo Corp Q4 GAAP Earnings Per Share $0.01

* QTRLY ‍TOTAL REVENUE, INCLUDING ROYALTY AND OTHER REVENUE, INCREASED 22.9% TO $225.2 MILLION​ Source text for Eikon: Further company coverage:

Feb 27 2018

BRIEF-Masimo Corp‍ Announced FDA Clearance Of Next Generation Sedline Brain Function Monitoring​

* MASIMO CORP - ‍ ANNOUNCED FDA CLEARANCE OF NEXT GENERATION SEDLINE BRAIN FUNCTION MONITORING​ Source text for Eikon: Further company coverage:

Jan 29 2018

BRIEF-Masimo Announces FDA Clearance For Home Use Of Rad-97

* MASIMO ANNOUNCES FDA CLEARANCE FOR HOME USE OF RAD-97™ Source text for Eikon: Further company coverage:

Jan 09 2018

BRIEF-Masimo ‍announces FDA clearance and U.S. release Of full family of NomoLine capnography sampling lines​

* ‍ANNOUNCES FDA CLEARANCE AND U.S. RELEASE OF FULL FAMILY OF NOMOLINE CAPNOGRAPHY SAMPLING LINES​ Source text for Eikon: Further company coverage:

Nov 27 2017

Earnings vs. Estimates